{
  "scores": {
    "rubric_version": "v3.0-2025-10-14",
    "items": {
      "Title": {
        "score": 1,
        "evidence": "Randomised Controlled Trial on Post-Operative Radiotherapy in Resected NSCLC"
      },
      "Trial_Design": {
        "score": 1,
        "evidence": "Participants were randomly assigned to receive either PORT using modern techniques or no PORT."
      },
      "Participants": {
        "score": 1,
        "evidence": "This multicenter randomised controlled trial included patients with resected NSCLC."
      },
      "Intervention": {
        "score": 2,
        "evidence": "Participants were randomly assigned to receive either PORT using modern techniques or no PORT."
      },
      "Objective": {
        "score": 1,
        "evidence": "This trial assesses the impact of PORT on disease-free survival (DFS) and overall survival (OS)."
      },
      "Method_Outcome": {
        "score": 2,
        "evidence": "The primary outcome was DFS over a 5-year period."
      },
      "Randomisation_Allocation": {
        "score": 2,
        "evidence": "Randomisation was computer-generated, and allocation was concealed."
      },
      "Blinding": {
        "score": 1,
        "evidence": "Blinding was not applied to patients or clinicians, but outcome assessors were blinded."
      },
      "Number_Randomised": {
        "score": 2,
        "evidence": "A total of 501 patients were randomised, with 250 in the PORT group and 251 in the control group, recruited between 2010 and 2021."
      },
      "Number_Analysed": {
        "score": 1,
        "evidence": "In the intention-to-treat analysis, PORT significantly reduced mediastinal recurrence."
      },
      "Result_Outcome": {
        "score": 3,
        "evidence": "PORT significantly reduced mediastinal recurrence (HR 0.71, 95% CI: 0.51\u20130.97) but did not improve DFS or OS (HR 1.02, 95% CI: 0.68\u20131.52)."
      },
      "Harms": {
        "score": 1,
        "evidence": "Adverse events were more frequent in the PORT group, with grade 3 or 4 cardiopulmonary toxicities in 11% compared to 5% in the control group."
      },
      "Trial_Registration": {
        "score": 1,
        "evidence": "Trial registration: NCTXXXXXXX"
      },
      "Funding": {
        "score": 1,
        "evidence": "Funding: Supported by [Funding Source]."
      }
    },
    "total_score": 20,
    "max_score": 25
  },
  "model": "gpt-4o"
}